SOUTH SAN FRANCISCO, Calif., June 11, 2025 /PRNewswire/ -- Deep Apple Therapeutics, Inc. announced today a research collaboration and exclusive worldwide license agreement with Novo Nordisk to ...

Zinger Key Points Deep Apple could receive up to $812 million in payments plus royalties from Novo Nordisk. Novo Nordisk gains exclusive global rights to commercialize oral GPCR-targeted drugs.

Deep Apple Therapeutics Inc. could bring in as much as $812 million in a new collaboration and license deal with Novo Nordisk A/S. The total includes an unspecified up-front payment, research costs ...

Deep Apple Therapeutics, Inc. announced on Wednesday a research collaboration and exclusive worldwide license agreement with Novo Nordisk A/S (NYSE:NVO) to discover, develop, and commercialize ...